Table 3.
Final analysis of primary and secondary endpoints. Data show the absolute difference (95% Interval Estimate) between 400mg CBD (n=24) and placebo (n=23) and between 800mg (n=23) and placebo (n=23). Separate analyses are presented for treatment weeks only and up to the final follow up
| Treatment weeks | Up to final follow up | |||||||
|---|---|---|---|---|---|---|---|---|
| 400mg vs Placebo | 800mg vs Placebo | 400mg vs Placebo | 800mg vs Placebo | |||||
|
|
|
|
|
|||||
| THC-COOH creatinine (ng/ml) | -94.21a | (-161.83, -35 56) | -72.02a | (-135.47, -19.52) | -29.18 | (-52.08, -7.25) | -13.20 | (-37.58, 12.10) |
| Days abstinent | 0.48a | (015, 0.82) | 0.27a | (-0.09, 0.64) | 0.03 | (0.00, 0.07) | -0.02 | (-0.06, 0.03) |
| Cannabis Withdrawal Scale | -0.34 | (-1.14, 0.50) | -1.26 | (-2.13, -0.39) | -1.32 | (-1.89, -0.06) | -2.50 | (-3.08, -1.93) |
| Urinary cotinine:creatinine (ng/nl) | -72.31 | (-194.35, 36.57) | -36.08 | (-163.46, 104.28) | -66.52 | (-157.06, 13.10) | -56.60 | (-145.36, 35.19) |
| Cigarettes smoked | -5.04 | (-6.57, -3.47) | 8.66 | (6-89, 10.26) | -1.32 | (-1.89, -0.60) | -2.50 | (-3.08, -1.93) |
| Alcohol units consumed | I5.32 | (-3.60, 49.27) | -8.49 | (-17.27, 0.44) | 0.86 | (-2.82, 3.84) | -I.50 | (-4.83, 1.04) |
| Pittsburgh Sleep Quality Index | 0.84 | (0.15, 1.57) | 0.16 | (-0.57, 0.81) | 0.55 | (0.21, 0.92) | 0.46 | (0.08, 0.82) |
| Beck Depression Inventory | 0.34 | (-0.47, 1.17) | 0.14 | (-0.70, 1.00) | -0.48 | (-0.76, -0.21) | -0.21 | (-0.49, 0.07) |
| Beck Anxiety Inventory | 1.41 | (0.65, 2.17) | -1.29 | (-1.97, -0.62) | 0.01 | (-0.25, 0.34) | -0.52 | (-0.82, -0.27) |
a
Primary endpoint